Vés al contingut

A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase: The ACTION Study.

  • Codi protocol: PA-ADPKD-301
  • Codi EudraCT: 2021-003062-12
  • Grup de recerca: Nefrologia i Trasplantament Renal
  • Servei: Nefrologia
  • Investigador/a principal:  Agraz Pamplona, Irene
  • Malaltia: Malalties del sistema genitourinari
  • Fase: Fase III